

Supplementary Table 9 Subgroup analyses of liver histology improvement across therapeutic targets based on different durations.

Note: ACC, acetyl-coenzyme A carboxylase; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GCG, glucagon; GIP, glucose-dependent insulintropic polypeptide; PPAR, peroxisome proliferator-activated receptor; THR, thyroid hormone receptor; RA, receptor agonist.

Supplementary Table 9.1. Interventions with ≤ 36 weeks for fibrosis improvement

Note: Fibrosis improvement means fibrosis improvement at least one stage without steatohepatitis worsening. The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as odds ratio and 95% confidence interval (CI). For instance, the odds ratio in fibrosis improvement at least one stage without steatohepatitis worsening for FGF21 analogue compared to placebo is 4.21 (95%CI: 1.90 to 9.35).

FGF21 analogue					
1.92 (0.61, 6.07)	FGF19 analogue				
0.89 (0.18, 4.38)	0.46 (0.09, 2.31)	d-(R)- Pioglitazone			
1.41 (0.48, 4.17)	0.73 (0.24, 2.26)	1.59 (0.32, 7.78)	PPAR agonist		
3.21 (0.92, 11.25)	1.67 (0.47, 5.97)	3.62 (0.67, 19.58)	2.28 (0.66, 7.91)	THR- β agonist	
4.21 (1.90, 9.35)	2.19 (0.95, 5.02)	4.75 (1.19, 18.94)	2.99 (1.37, 6.53)	1.31 (0.50, 3.46)	Placebo

Supplementary Table 9.2. interventions with >36 weeks for fibrosis improvement

Note: Fibrosis improvement means fibrosis improvement at least one stage without steatohepatitis worsening. The columns represent the comparison of the row target class to the column target class. The effect estimates are expressed as odds ratio and 95% confidence interval (CI). For instance, the odds ratio in fibrosis improvement at least one stage without steatohepatitis worsening for GLP-1 RA compared to placebo is 2.02 (95%CI: 1.48 to 2.74).

FGF21 analogue						
1.09 (0.29, 4.03)	GLP-1 RA					
1.01 (0.27, 3.78)	0.92 (0.57, 1.49)	THR- β agonist				
0.81 (0.21, 3.14)	0.75 (0.43, 1.30)	0.81 (0.45, 1.46)	FXR agonist			
0.64 (0.14, 2.89)	0.59 (0.25, 1.39)	0.64 (0.27, 1.54)	0.79 (0.32, 2.00)	GLP-1/GCG dual RA		
0.73 (0.16, 3.37)	0.67 (0.27, 1.65)	0.73 (0.29, 1.83)	0.90 (0.34, 2.36)	1.13 (0.35, 3.63)	GLP-1/GIP dual RA	
2.20 (0.61, 7.84)	2.02 (1.48, 2.74)	2.18 (1.51, 3.15)	2.70 (1.70, 4.29)	3.40 (1.53, 7.56)	3.01 (1.29, 7.02)	Placebo

Supplementary Table 9.3. Interventions with ≤ 36 weeks for steatohepatitis resolution

Note: Steatohepatitis resolution means steatohepatitis resolution without fibrosis worsening. The effect estimates are expressed as odds ratio and 95% confidence interval (CI). For instance, the odds ratio in steatohepatitis resolution without fibrosis worsening for PPAR agonist compared to placebo is 3.43 (95%CI: 1.77 to 6.68).

FGF21 analogue					
1.56 (0.36, 6.69)	FGF19 analogue				
4.25 (0.90, 19.94)	2.72 (0.50, 14.78)	d-(R)- Pioglitazone			
1.74 (0.56, 5.37)	1.12 (0.30, 4.17)	0.41 (0.10, 1.69)	PPAR agonist		
4.38 (1.10, 17.41)	2.81 (0.60, 13.11)	1.03 (0.20, 5.24)	2.52 (0.73, 8.64)	THR- β agonist	
5.97 (2.41, 14.84)	3.83 (1.23, 11.95)	1.41 (0.40, 4.91)	3.43 (1.77, 6.68)	1.36 (0.48, 3.85)	Placebo

Supplementary Table 9.4. Interventions with >36 weeks for steatohepatitis improvement

Note: Steatohepatitis resolution means steatohepatitis resolution without fibrosis worsening. The effect estimates are expressed as odds ratio and 95% confidence interval (CI). For instance, the odds ratio in steatohepatitis improvement without fibrosis worsening for GLP-1 RA compared to FXR agonist is 1.84 (95%CI: 0.61 to 5.58).

FGF21 analogue							
0.30 (0.04, 2.12)	GLP-1 RA						
0.27 (0.04, 2.02)	0.92 (0.31, 2.76)	THR- β agonist					
0.49 (0.07, 3.70)	1.65 (0.53, 5.16)	1.79 (0.54, 5.95)	PPAR agonist				
0.55 (0.08, 4.02)	1.84 (0.61, 5.58)	2.00 (0.62, 6.40)	1.12 (0.34, 3.73)	FXR agonist			
0.13 (0.01, 1.15)	0.43 (0.10, 1.83)	0.46 (0.10, 2.07)	0.26 (0.06, 1.20)	0.23 (0.05, 1.03)	GLP-1/GCG dual RA		
0.10 (0.01, 0.96)	0.32 (0.06, 1.61)	0.35 (0.07, 1.82)	0.19 (0.04, 1.05)	0.17 (0.03, 0.91)	0.74 (0.11, 5.00)	GLP-1/GIP dual RA	
1.36 (0.22, 8.36)	4.57 (2.17, 9.60)	4.96 (2.17, 11.32)	2.77 (1.15, 6.70)	2.48 (1.10, 5.61)	10.67 (3.07, 37.07)	14.33 (3.39, 60.61)	Placebo